Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
November 5, 2020
Earnings Call Speaker Segments
Jennifer Ruddock
executiveCrystal, thanks. Hello, everyone, and I appreciate you being with us this afternoon. Joining us are our President and CEO, Howard Robin; our COO, Gil Labrucherie; Dr. Jonathan Zalevsky, who leads Research and Development; and Dr. Wei Lin, who leads Development. During this call, we anticipate delivering forward-looking statements about our business, covering clinical trial enrollment and results, when future clinical trials will occur and what we plan for them, when future clinical data will be presented and our plans for those presentations, how our drug candidates might perform therapeutically, what health authority regulatory actions and decisions may result and our plans concerning them, what we estimate and predict regarding how the COVID-19 pandemic affects our business and clinical trials, financial guidance, and certain other statements about our business's future. Since these forward-looking statements concern the future, they carry inherent uncertainties and risks that are hard to foresee, and many lie beyond our control. Significant risks and uncertainties appear in the Form 10-Q we filed on August 7, 2020, which you can find at www.sec.gov. We are not obligated to update any of these forward-looking statements, whether from new information, future developments, or otherwise. A webcast replay will be accessible on the IR page at Nektar's website, nektar.com. Before I pass the call to Howard, since all of us are dialing in from different places, I will moderate the Q&A portion for our team, which lets us steer clear of technical problems during that portion; we thank you for your patience while we work to make sure there are no technology disruptions for everyone listening. Having said that, I will turn the call over to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveThank you, Jennifer, and I appreciate all of you taking the time to be with us today. Throughout the last quarter, we kept moving forward with the joint development effort for bempeg alongside Bristol-Myers Squibb, our partner, and that included kicking off 2 fresh trials during Q3 — a registrational phase III study in adjuvant melanoma that Nektar is sponsoring, plus a Phase I/II trial sponsored by BMS that broadens bempeg's development in renal cell carcinoma through a triplet approach combining bempeg and nivo with a TKI agent. For our lead cytokine candidate, the bempeg collaboration with BMS now encompasses 6 distinct ongoing studies, 5 of which are registrational. Taken together, the registrational effort behind bempeg is intended to reach a fairly sizable group of patients spanning melanoma, renal cell carcinoma and bladder cancer. This joint program involving bempeg plus nivo represents a substantial commitment to bempeg, and it highlights how enthusiastic everyone is about the potential for this unique, differentiated IL-2 agent to function as a key backbone therapy alongside the checkpoint inhibitor nivolumab when treating solid tumors. In parallel, we're pushing ahead on bempeg's development with the checkpoint inhibitor pembrolizumab through the PROPEL study in non-small cell lung cancer, which ranks among the biggest solid tumor opportunities for bempeg. Enrollment for PROPEL is running well beyond what we had projected, and I'll turn things over to Wei, who can say more about that program — more about the headway we've achieved in that trial — shortly. Next week at SITC, several fresh data sets from our immune-oncology pipeline will be presented, among them updated PIVOT-02 results for bempeg in melanoma covering over 30 months of follow-up for those patients, along with the initial data from our NKTR-255 program, our IL-15 candidate. As all of you are aware, for PIVOT-02 we shared very impressive findings for bempeg plus nivo in this cohort at SITC last year, showing a high complete response rate of 34%, with 42% of patients seeing a 100% reduction of their RECIST target lesions. And notably, we recently announced that at 21 months, a median PFS had still not been reached in that cohort. Those findings resulted in a breakthrough therapy designation for bempeg and 2 sizable Phase III trials in melanoma, 1 in first-line metastatic melanoma and 1 in the adjuvant setting. The addressable market opportunity for bempeg across these 2 areas is quite substantial; for reference, combined OPDIVO and KEYTRUDA sales in this setting come to roughly $2 billion. We're eager to share these updated PIVOT-02 melanoma results next week at SITC; the efficacy benefit shown by bempeg plus nivo in this study continues to impress us, and we remain highly optimistic as we look ahead to the Phase III data readout. With bempeg plus nivo, our ultimate aim is to bring about a new treatment paradigm in melanoma for the benefit of patients. Additionally, Nektar is going to hold an analyst event on November 11, bringing together leading oncology experts to talk through this data along with the other presentations we're making at SITC, and we'd love for you to be part of that conversation. On top of that, we recently kicked off a second Phase I/II trial involving NKTR-255, which is our IL-15 asset and the next cytokine sitting in our pipeline. This fresh study is going to look at NKTR-255 in people who have solid tumors. That comes alongside the Phase I trial already underway testing NKTR-255 in non-Hodgkin's lymphoma and multiple myeloma patients. Just to remind everyone, in contrast with other IL-15 methods, NKTR-255 was built to take advantage of the complete biology behind the IL-15 pathway — in other words, NKTR-255 is purposefully engineered so it can grab every receptor-ligand interaction that's targetable within the IL-15 agonist pathway. Our view is that this positions NKTR-255 to work as a powerful expander of natural killer cells, and also to encourage the survival and growth of memory CD8+ T cells. Right now there's a lot of excitement around natural killer cell agents, since this mechanism for killing cancer cells is intended to strengthen and bring back the immune response in patients, which may help them battle their cancer more successfully. Turning to NKTR-358, yesterday we shared fresh data at the American College of Rheumatology conference, and I realize a good number of you tuned into that presentation. What stood out most was a dose-dependent rise in T regulatory cells among lupus patients who received NKTR-358, alongside a reduction in disease symptomology on the order of magnitude. During Q3, Lilly launched a Phase II trial in lupus patients, and they're also getting ready for a second Phase II trial in ulcerative colitis patients. Those come on top of the 2 Phase Ib trials Lilly already has running for NKTR-358 in atopic dermatitis and psoriasis. NKTR-358 is a first-in-class investigational Treg stimulating agent, engineered to fix an underlying immune imbalance in autoimmune condition patients, a large number of whom have fewer of their own T regulatory cells and ones that don't function properly. We're extremely happy that Lilly is pushing NKTR-358 forward, and we're eager for this development program to keep growing. As everyone is aware, we're still operating within the shifting COVID-19 environment, and I feel a lot of pride in our employees, who are putting in hard work to keep business interruptions to a minimum. Along those lines, I'm happy to share that we're mostly on schedule with the trial time lines we talked about before, which were reviewed — that were reviewed during our August financial results call. Like I said before, we're staying sharply focused on the 5 ongoing registrational oncology studies involving bempeg plus nivolumab. Those consist of the first-in-line metastatic melanoma study, the first-line bladder cancer study, the first-line renal cell carcinoma study, the muscle-invasive bladder cancer study and the adjuvant melanoma study; in a moment we'll walk through the whole bempeg registrational program in detail, but first I want to call out a few time line highlights from the registrational program for the PROPEL study in non-small cell lung cancer. At this point, 3 registrational trials exist for bempeg, and first data readouts from all of them can be seen within the same window. Those trials are the metastatic melanoma one, the bladder cancer one for cisplatin-ineligible patients, and the metastatic RCC one. Regarding the metastatic melanoma trial, which BMS is conducting, as was mentioned during the prior quarter, first data are anticipated in late 2021 or early 2022 owing to COVID-19 related delays affecting that trial. Three endpoints are included in this trial: ORR, PFS and OS; these endpoints are sequential, and the one intended to support full approval is PFS. For the bladder cancer trial, a comparable timeline is anticipated, with ORR and duration of response reported during the first part of 2022. As for RCC, the initial interim analysis for overall survival is anticipated around that same period. In non-small cell lung cancer, patients are being actively enrolled in the ongoing PROPEL trial of bempeg combined with Merck's pembrolizumab, the established standard of care in this setting. Our strategy for a registrational program for bempeg in first-line non-small cell lung cancer will be informed by these data. Investigator interest in this trial has been significant, and consequently a recent rise in patient enrollment has been observed. Preliminary ORR data are now anticipated during the first part of 2021 for approximately 30 patients with a minimum of 2 scans on treatment drawn from the non-small cell lung cancer cohorts of this trial. As you'll recall, the original expectation was that data would be available for only 10 to 20 patients. So the speed of enrollment is very pleasing to us; the third quarter ended with a strong balance sheet, holding over $1.2 billion in cash and investments and no debt. This strong financial position lets us concentrate on advancing our pipeline of auto-immunocology candidates, among them the lead cytokine programs, IL-2 and IL-15, which have broad applicability across a wide range of tumor types. And now I'll hand the call over to Wei to review the bempeg development program in greater detail.
Wei Lin
executiveHoward, thank you. I'd like to go over the current status and expected timing for the bempeg registrational program. Five separate registrational trials make up that program, and together they're meant to position bempeg as the preferred option in front-line metastatic and adjuvant melanoma, as well as kidney cancer and bladder cancer. Let's begin with the first-line metastatic melanoma study, which our partner BMS has been conducting: enrollment was successfully restarted this summer by BMS in numerous countries. More investigative sites have since been brought on board to compensate for what was lost while COVID-19 halted activity. As Howard mentioned earlier, breakthrough therapy designation has been awarded to us for bempeg plus nivo, on the basis of the elevated complete response rate observed among first-line melanoma patients. The Phase III study has three goals we're measuring: overall response rate, which we call ORR; progression-free survival, or PFS; and overall survival, OS. The first data we'll share comes from an interim look that pits ORR in the bempeg plus nivo doublet group versus ORR in the nivo monotherapy group, and it will include about two-thirds of the people enrolled who've been followed for at least 6 months. We designed that endpoint to back a potential early accelerated approval submission for the doublet, which would allow us to bring this novel therapy to patients sooner should it be approved. When it comes to gaining full approval for bempeg in the U.S. and Europe, the submission will depend on PFS and OS. Given how high our complete response rate is, a lot of you have wondered whether that measure could serve as a registration endpoint in place of ORR. Following talks with several global health authorities, BMS and Nektar decided to keep the protocol as is, with the endpoints already in place. So the trial proceeds with its original 3 endpoints: ORR, PFS and OS. Under the trial's original design, the median PFS for the nivolumab arm is assumed to be similar to the 6.7 months seen in CheckMate 067. For our trial, per that original design, the PFS analysis is expected roughly 6 to 7 months following the ORR analysis. That said, PFS is event-driven, and several other factors could shift this timing too, such as the time required for independent blinded readout review of the data. As for the registrational trial in first-line metastatic bladder cancer, we hit our enrollment target in September. To recap, the primary endpoints there are ORR and duration of response, assessed through central radiology review, for approximately 110 metastatic bladder cancer patients whose baseline PD-L1-positive score is confined to 10 or lower; this will underpin a possible accelerated approval submission. Duration of response matters a great deal — it's a key endpoint for this cisplatin-ineligible population, since it was the differentiating factor behind accelerated approvals for single-agent checkpoint inhibitors in this setting. In comparison to the usual treatment regimen of gemcitabine plus carboplatin, this study is designed to track patients for at least a year and a half, which will give us a clearer picture of response durability. As a result, we now anticipate initial findings from this study in early 2022. Regarding the first-line renal cell carcinoma study, our anticipated patient accrual remains unchanged, so we still foresee the initial interim review of the primary overall survival endpoint occurring during the first quarter of 2022, consistent with what we previously communicated. Based on the initial guidance that was released for the combination of bempeg and nivo in renal cell carcinoma, BMS and Nektar have developed a thorough strategy to advance bempeg in this indication. Therefore, as Howard mentioned previously, in addition to the Phase III study that is already underway, BMS recently launched a Phase I/II study in this setting, and it incorporates a tyrosine kinase inhibitor. This new study assessed again the three-drug regimen of bempeg and nivolumab along with either axitinib or cabozantinib, and it will subsequently move into a second portion, where the triplet of bempeg, nivo plus a TKI will be compared with the doublet of nivo plus TKI in patients who have RCC. Regarding the muscle-invasive bladder cancer study that BMS has been conducting, about 540 patients are being enrolled. They'll get either bempeg combined with nivolumab or nivolumab by itself, with treatment lasting 12 months after surgery. Recruitment is ongoing, and additional sites have been brought on board over the course of this year. Because this study takes longer, our expectation is that the initial data readout will come in 2024. Finally, turning to the adjuvant melanoma trial, during Q3 we got this important extra Phase III registrational study underway significantly ahead of schedule, and it is now actively enrolling patients. Howard mentioned that this study lets us establish bempeg as a fresh benchmark for melanoma care, and it considerably expands the patient population that might gain from this therapy. Enrollment for this trial will total 950 individuals, who will receive treatment for 12 months following surgery, with event-free survival serving as the endpoint. We also anticipate the first results from this study in 2024. Regarding PROPEL, which is our non-small cell lung cancer study pairing the drug with pembrolizumab, we've seen tremendous enthusiasm from top thoracic cancer institutions across the U.S. and Europe. Because of that, the number of people enrolled has gone beyond what we projected over the recent months. As a result, our expectation now is that we'll obtain additional data covering each of the three PD-L1 groups — under 1%, between 1% and 49%, and 50% or higher — from this study, based on information gathered from roughly 30 subjects who completed at least two scans, with that information becoming available during the first quarter of 2020, and likewise from about 30 subjects with two or more scans, available in the opening portion of 2021. And as we mentioned a week ago, we've launched a proof-of-concept clinical study of bempeg to treat patients with COVID-19. It's clear by this point that America kept setting records for the highest number of new coronavirus infections in a single day. We recognized a chance to assess bempeg as a possible way of tackling an underlying process seen among individuals who eventually develop a more serious form of the illness; specifically, these patients show low lymphocyte counts at baseline, which might stem from their bodies failing to mount a sufficient adaptive immune response against the viral infection. Our initial trial locations are up and running in Texas and Florida, plus an additional site in Pennsylvania at Temple. Our hope is that bempeg may offer a distinctive treatment strategy and earlier intervention for patients who must produce a stronger T cell response against this virus. At this point, I'd like to turn the call over to JZ, who will go into further detail about our NKTR-358 and NKTR-255 programs.
Jonathan Zalevsky
executiveThank you, Wei. I'll start by giving a quick status report on NKTR-358. A number of autoimmune conditions, systemic lupus among them, come with lower Treg counts, diminished Treg activity, and/or less interleukin-2 being produced. These Treg deficits play a meaningful role in how such autoimmune diseases develop; through NKTR-358, we're aiming to correct those Treg abnormalities and to create an IL-2-like molecule capable of stimulating Tregs selectively, and more effectively than native IL-2 does. Yesterday at ACR, we presented fresh results from our Phase Ib trial of NKTR-358 in people with mild-to-moderate lupus. I want to highlight several important points. As we shared at EULAR earlier this year, treatment with NKTR-358 produced a selective, dose-dependent growth of CD25 bright Tregs. That effect held up across repeated dosing. In yesterday's data, we demonstrated that NKTR-358 brought about dose-dependent increases in Treg activation markers as well as genes tied to Treg functionality. We also, for the first time, reported on disease activity seen among patients given NKTR-358. The trial included individuals with mild-to-moderate disease, and each patient got just 3 doses of NKTR-358. Treatment duration was therefore quite short. In our analysis, we examined a subgroup of patients whose disease activity was moderate, with CLASI-A scores at or above 4. Among those individuals, NKTR-358 produced a dose-dependent drop in CLASI-A score relative to baseline. Importantly, every dose level of NKTR-358 was linked to a decrease in CLASI-A among these patients, whereas those on placebo showed none. By day 43, 7 of 18 patients had achieved a reduction of 4 points or more versus their starting scores. And a single patient, receiving the top dose of 24 micrograms per kilogram, saw their CLASI-A score fall from 22 at baseline down to 5 by day 43 — which was 2 weeks following the final NKTR-358 dose. That's truly exciting. Seeing NKTR-358 deliver a dose-dependent decrease in CLASI-A composite clinical scores among moderate SLE patients after merely 3 treatment cycles fits nicely alongside both the PK findings on NKTR-358 exposure and the PD findings on Treg induction. On the whole, we're thrilled about this data from ACR 2020, since we've now shown that among SLE patients, NKTR-358 is able to generate a far greater magnitude of Treg increase than low-dose IL 2 can. NKTR-358's effects depend on dose, and we're able to pick up molecular, cellular, and clinical shifts in these patients following treatment. These encouraging Phase I results for NKTR-358 have prompted our partner, Eli Lilly, to begin planning a number of studies. This covers 2 distinct Phase Ib trials, one in atopic dermatitis and one in psoriasis; the fresh Phase II lupus trial, which kicked off during Q3; plus a Phase II trial in ulcerative colitis that's in the planning stages; within the lupus Phase II trial, participants are assigned randomly to 1 of 3 dose levels of NKTR-358 or to placebo, with dosing administered every 2 weeks across a 24-week treatment period. The main endpoint for that Phase II trial is the decrease measured on the SLEDAI-2K scale. Among the secondary endpoints are the percentage of subjects achieving an SRI-4 response, a BILAG-based BICLA response, and a low disease level as defined by the lupus low disease activity state, or LLDAS. Additionally, we'll characterize PK, CD, and immunogenicity among treated patients. Measurements of these endpoints will occur at week 24, and we anticipate the trial wrapping up somewhere between 18 and 24 months; let's now shift focus to NKTR-255, our IL-15 agonist program and the next cytokine therapy we have in clinical development. As Howard mentioned previously, the scientific community increasingly views the IL-15 mechanism as critically important for engaging natural killer cell biology when treating cancer. And as you're aware, this research field is sparking a great deal of enthusiasm. NKTR-255 is built to capture the IL-15 pathway's full biology, since it drives both NK cell proliferation and CD8 memory T cell expansion. This gives us a broad array of possible development paths for NKTR-255 across both liquid and solid tumors; virology too has been demonstrated in our early research collaboration with Gilead. Given the pharmacological profile of NKTR-255, we're pushing ahead on multiple fronts with this program; right now we're running a Phase I trial in patients who have relapsed/refractory hematologic malignancy. Enrollment in this trial has been somewhat slower than we'd prefer owing to COVID-19 difficulties at Phase I trial sites, but we've recently added new sites, and the trial is now back on track. We anticipate finishing the monotherapy dose escalation portion of the trial during the first quarter of 2021. Following dose escalation, the trial will expand into several arms that will assess NKTR-255 as a monotherapy in NHL and will also assess NKTR-255 combined with daratumumab in multiple myeloma and combined with rituximab in NHL. We anticipate enrolling roughly 60 patients in this portion of the trial. We're also delighted to announce today that we've recently formed a new drug supply collaboration with Janssen. Janssen is going to supply DARZALEX FASPRO, their new subcutaneous form of daratumumab, which received approval for multiple myeloma in May of this year, and we're eager to assess the combination of NKTR-255 and plus DARZALEX FASPRO in multiple myeloma patients within our ongoing trial. And as noted, we anticipate opening the daratumumab combination cohort along with the rituximab combination cohort once the dose escalation portion of the trial concludes in the first quarter 2021. We've added a comprehensive biomarker component to the Phase I NKTR-255 trial, and it's assessing how the drug affects several immune cell populations recognized as key players in controlling tumors; particular attention is being paid to NK cell expansion, examination of NK cell subsets along with their activation and functionality, and the growth of CD8 T cells. Among the first patients dosed in our Phase I trial, we've already seen signs that the IL-15 pathway is being engaged, and we're eager to provide further information on that next week at SITC. Another thing we're quite enthusiastic about is that our second Phase I/II trial of NKTR-255 was recently launched, designed to test the combination with cetuximab across 2 separate groups of heavily refractory second and third-line patients who have metastatic colorectal cancer or metastatic head and neck cancer. Enrollment in the study overall will reach as many as 75 patients, and it will feature a dose escalation portion for the combo regimen, which afterward will be broadened into dedicated expansion cohorts for head and neck and colorectal cancer. Momentum behind the NKTR-255 program is building considerably, and we're looking forward to presenting early translational data from the initial dose escalation cohorts in our first-in-human Phase I trial at SITC next week; having said that, I'll hand the call over to Gil now so he can walk through the financials.
Gil Labrucherie
executiveAlright, thanks JZ, and good afternoon to all of you. During this call, I'll go over the financial guidance we've set for 2020. To begin, our financial standing is solid: at the close of the quarter, we held $1.2 billion in cash and investments, with zero debt on our balance sheet. Our intention remains to finish 2020 holding more than $1 billion in cash and investments. Now I'll move to the guidance for the year. For full year 2020, our GAAP revenue projection is unchanged, staying in the range of $140 million to $145 million. Within that figure, $50 million comes from milestone payments tied to BMS, while $90 million to $95 million comes from royalties, product sales, and other revenue. Through the BMS collaboration, we recorded a $25 million milestone during Q1 for kicking off the muscle-invasive bladder cancer study, and then a second $25 million milestone in Q2 tied to beginning the adjuvant melanoma study. Regarding GAAP R&D expense guidance, we now expect 2020 GAAP R&D expense to fall somewhere between $415 million and $425 million, and that figure includes roughly $60 million in noncash depreciation along with stock compensation expense. Several things led to this lowered R&D expense forecast, among them the timing of R&D spending on some of our earlier-stage and non-oncology programs because of COVID, noncash stock compensation and depreciation expense coming in below what we had projected, and decreased travel and other costs stemming from the impact of the COVID-19 pandemic. For G&A expense in 2020, we continue to expect a range of $105 million to $115 million, which includes about $45 million of noncash stock compensation and depreciation expense. Last, because of how the COVID-19 pandemic affected the financial markets, along with lower-than-expected yields from our investment portfolio, our updated projection for interest income in 2020 is roughly $20 million. The important thing is that we've seen no significant realized or unrealized losses across our investment portfolio. We keep tight control over our operating expenses and stay sharply focused on carrying out our wide-ranging portfolio of research and development programs. And as I mentioned before, our plan is still to close out 2020 holding more than $1 billion in cash and investments. With that, I'll turn the call over for questions. Operator?
Peter Lawson
analystWaleed here, sitting in for Peter. I've got a question about your PIVOT study in frontline melanoma — how ought we to frame the efficacy bar for it? What kind of results in your pivotal data would count as positive and could help make the case for approval?
Jennifer Ruddock
executiveThanks, Waleed. Wei, I'd like you to take that one.
Wei Lin
executiveYeah, absolutely. The way we tend to examine this dataset is by focusing on the control arm, which at present consists of standard care, namely nivolumab. That means our comparator has been established quite effectively, is broadly acknowledged across the globe, and could function as the foundation for registration worldwide. So our registrational approach is essentially a two-step affair. First, we intend to pursue accelerated approval grounded in ORR, and after that a complete approval grounded in progression-free survival, with a later supplement grounded in overall survival. So really, it comes down to these two benchmark figures. In this setting, nivolumab's baseline response rate sits at approximately 40%. We'd therefore want to surpass that with ORR; that's about 10% to 15% above the response rate for nivolumab as a single agent. I believe we can then show unequivocally, in a statistically significant manner, that our response rate is superior to nivolumab's. So that, alongside durable response and the safety profile, becomes the final package enabling a third approval grounded in ORR. Then afterward, progression-free survival, PFS, which would let us secure full approval, will serve not merely as a second attempt at the goal, but also as a possible conversion should we obtain third approval grounded in ORR. And that will be measured against the 6 to 7 months of PFS historically seen with nivolumab in this setting. As many of you know, we've generally had early-phase data in PIVOT-02, and particularly concerning our melanoma cohort, the patients enrolled in that cohort have in fact seen rather remarkable benefit from combining bempeg plus nivolumab with. I believe on the last prior earnings call, even at 21 months of follow-up, the median progression-free survival had not been reached. So at the upcoming SITC, we'll offer a further update with longer follow-up. And so every one of us is definitely quite encouraged by what we've seen in PIVOT-02. And if the Phase III registrational study could reproduce the findings from PIVOT-02, then we ought to see a rather substantial margin of improvement in PFS relative to nivolumab as a single agent. And that would deliver enormous value in extending survival for patients with first-line metastatic melanoma.
Alexander Duncan
analystI have two questions—one about bempeg and another regarding 255. First, on bempeg: it's encouraging to observe the recent increase in PROPEL enrollment. I'd like to grasp the underlying factors a bit better, if you could say more. Is this mostly because the nivo-bempeg trial has been discontinued? Second, concerning the 255 monotherapy and the dose escalation update at SITC, which safety signals are you watching especially closely? Also, regardless of whether you determine the MTD, how will you apply the 255 monotherapy biomarker data to guide safe-dose selection for use in the combination cohorts? What I'm really asking is: how confident are you that combining 255 with RITUXAN, for instance, will not amplify an adverse event like infections and liver mets?
Jennifer Ruddock
executiveThanks, Alex. Wei, please respond to the first portion of the question regarding the PROPEL study; after that, JZ, I'll have you address the second one.
Wei Lin
executiveYeah, thank you. And yes, the PROPEL study, as you're aware, is one that we're hoping will serve as a registration study for first-line non-small cell lung cancer. With that goal in mind, we're working to generate data, and at present that's with the combination of bempeg and pembrolizumab, which builds on pembrolizumab as the existing standard of care for patients who are PD-L1-positive. So at this moment, with the COVID pandemic going on, everybody has run into enrollment difficulties; and our study team has handled this remarkably well. As we mentioned on an earlier earnings call, with PROPEL, although our plan was to open sites in Europe and the U.S. alike, we ran into some difficulties because Europe's first pandemic wave lined up with when we intended to initiate those sites. But we worked very diligently with the sites, figuring out the optimal moment to open them. And although there was initially a delay in getting European sites open, once that first pandemic wave had passed, we managed to get our sites up and running, and enrollment has been extremely brisk. I believe that simply shows that while pembro has genuinely delivered an enormous gain in overall survival for patients who suffer from non-small cell lung cancer, its monotherapy benefit remains limited to roughly 2 years or so; so these patients still have a huge need for improved therapy, particularly for options that spare them chemo; and therefore — and that's shown by how well this trial has enrolled once we had the sites in the U.S. and Europe up and running. So we've observed a step-by-step improvement for the combination, and it also mirrors the need that physicians keep seeing, despite pembro monotherapy being a wonderful, well-established standard of care, to truly build on it and genuinely improve it and extend patients' lives in its indications. So we're definitely excited about the study, excited about the data we can deliver next year, and also about the potential — the data and assessing whether a Phase III could follow up on that data analysis.
Jonathan Zalevsky
executiveAppreciate that, Wei. And Alex, thanks for raising this. Now, on the topic of 255 — as everyone's aware, this trial is the first time it's being given to humans. During the dose escalation portion, we're enrolling individuals whose disease is fairly advanced, meaning either non-Hodgkin's lymphoma or multiple myeloma, and administering rising doses of NKTR-255 through an intravenous route. What we're watching for on the safety side includes signals that came out of our preclinical toxicology work and other studies, plus what we've learned from experience with groups involved in other programs where IL-15 has been used in patients. So we're monitoring for those very same types of effects. We're evaluating the important cytokine-associated toxicities and adverse events. We're examining secondary cytokines, which matter greatly since we naturally expect that IL-15 agonism of cells carrying IL-15 receptor complexes will trigger cytokine responses. On top of that, we're looking into the downstream cellular dynamics tied to IL-15. As you're aware, it can produce numerous homeostatic effects. So your question was whether the MTD has been identified in this study — it hasn't, and dosing continues to escalate. We also have a really extensive biomarker effort that helps guide how we pick doses. Once again, this is a page from the playbook we previously ran, say, with bempeg, where we track many markers that measure target engagement of IL-15 with its receptors. You can measure that in the natural killer cell population — looking at cellular response shifts, activation, functional changes of those cells and their subsets — and likewise in the CD8 population, and you can do this both in blood and in secondary tissues too. So all of that feeds into our dose selection and gives us extremely strong confidence that we've hit the target or are achieving the pharmacodynamic effect we're after. Then, once we settle on a go-forward recommended Phase II dose for the expansion cohort, you're completely correct — we will focus heavily on what occurs when we pair either daratumumab or rituximab. In that situation, as you know, both of these are antibodies possessing an IgG1. They're also antibodies recognized for having something akin to a tumor lysis syndrome. That can show up when there's extremely rapid lysis of B cells — with rituximab, for instance, when it clears them so fast, via clearance either through the liver or through the spleen in fixed tissue cells. So we'll be watching those things extremely carefully; we'll be watching cellular changes extremely carefully and also monitoring patients extremely carefully to make sure we aren't observing any kind of adverse events from the combination, because in fact we aim to do precisely the opposite — meaning substantially better cell clearance not only within blood compartments, but especially within the secondary lymphoid compartments where these tumors live.
Daniel Wolle
analystDaniel Wolle here, filling in for Jessica Fye. Still on 255 — you mentioned that your initial push into solid tumors is in colorectal cancer along with head and neck. Could you walk us through what the opportunity for 255 looks like in solid tumors? What makes it possible to pick those 2 distinct tumor types? And beyond that, as you move this program ahead, do you view combination therapy as the best path — or could it also be assessed on its own as a monotherapy?
Jennifer Ruddock
executiveYes. Wei, I'd like you to handle that one.
Wei Lin
executiveAbsolutely. We genuinely perceive a massive opening when it comes to solid tumors for IL-2 drugs such as 255, given that monoclonal antibodies have now turned into the go-to treatment across oncology broadly — in blood cancers as well as solid tumors. In fact, Herceptin, used against HER2-positive breast cancer, ranked among the earliest monoclonal antibodies approved for any cancer type. So there's a lengthy track record, a heritage of monoclonal antibody study turning into a firmly established standard of care across a great many tumor categories. And when we consider how to advance 255 in the solid tumor arena, we carefully examine which indications are ones where a monoclonal antibody is still utilized not in first line but in later lines, and where the current standard of care still leaves substantial space for better outcomes; that is precisely what directed us toward cetuximab in the head and neck cancer setting, along with colorectal cancer. To be specific about head and neck cancer, cetuximab for a considerable period was first approved as a single agent in a late-line context, yet ultimately shifted into first-line usage on the strength of the EXTREME trial. After that, the combination of cetuximab with platinum-based chemotherapy and 5-FU became the accepted standard of care for head and neck cancer in the first-line setting for a good while, until more recently when pembrolizumab plus chemotherapy surpassed that standard; and following that — so afterward cetuximab's role went back to being a monotherapy used in later lines. That shift opens the door to genuinely bettering the late-line advantage cetuximab actually delivers. When you examine the late-line context, cetuximab given alone achieves only roughly a 15% response rate. Clearly, then, considerable space remains for improvement; and the mechanism of action behind our 255 molecule is essentially to grow the NK cells, which play such a vital part in carrying out the ADCC activity of these monoclonal antibodies, cetuximab included; thus the mechanism strongly backs the theory that adding 255, by growing the NK cell population, would markedly boost the ADCC-driven activity of antibodies such as cetuximab and better the 15% response rate seen in late-line head and neck cancer; that's roughly the reasoning behind our choice to select cetuximab as one of the — in head and neck cancer as one of the initial indications to go after. Furthermore, a comparable scenario unfolds in colorectal cancer. Globally, colorectal cancer represents a considerably larger disease. Now the — cetuximab's usage is rather split. So to a significant degree, cetuximab gets used either in the first-line or second-line setting alongside a chemotherapy regimen — that's its full fury; but at certain centers, and by certain investigators, cetuximab is also employed as a single agent; so because of these differing patterns of use, we likewise spotted a chance to pair cetuximab as a single agent together with 255 in order to better the benefit that the single agent provides. Also once more, regarding single-agent activity in colorectal cancer within a later-line setting, it sits around 15%; if we were to succeed in that context, there would be space for us to advance into an earlier-line setting, where it is used alongside chemotherapy too. So I believe at this point — since both head and neck cancer and colorectal cancer present an opportunity to take advantage of the monoclonal antibody ADCC MOA and have well-established standard of care being used in a later-line setting, along with an efficacy bar that leaves enormous room for improvement, those were the reasons why one would take these indications and select cetuximab as a combination partner to begin with. Now, should we produce proof of concept with cetuximab in head and neck cancer or in colorectal cancer, that would let us proceed after showing this proof of concept grounded in this MOA to broaden the combination to other ADCC-based monoclonal antibodies in solid tumor, as well as the generation data in heme enabling us to advance in heme malignancies too. So — and to add to that, I think 255 truly has huge potential and could improve upon the current standard of care, which is in wide use of ADCC monoclonal antibodies that cover so many different tumor types.
George Farmer
analystWei, could you say a little about what would count as success in PROPEL? Those 30 patients are essentially going to be split across various PD-L1 subgroups — do you anticipate seeing any differences there? And I realize 30 patients is a solid number to reach, but with it divided among all these separate subgroups, things could get somewhat sparse within each one. Then, JZ, I know this came up some yesterday. But might you address what the CLASI-A score means and how it connects to the SLEDAI score in lupus, and how we should think about those 2 distinct scoring systems?
Jennifer Ruddock
executiveThank you, George. Wei, would you like to go ahead?
Wei Lin
executiveAbsolutely, I'll handle the first portion of that question. Thanks — it's a really good one. We've spent considerable time on this, since choosing the registrational objective is a major call for any drug's development. With bempeg specifically, and for the PROPEL study, as you're aware, today's standard of care splits that first-line metastatic non-small cell lung cancer population into 3 subgroups. Those are: PD-L1 expression below 1%, between 1% and 49%, and at or above 50%. We then have either early phase or registrational data to use as a benchmark against the historical figures pembrolizumab shows in each subgroup. Starting with the under 1% population: pembrolizumab given as a single agent, based on early phase data, actually showed a response rate of 7% to 8%. So genuinely in the single-digit range, within 5% to 10%, and that's our expectation. Right? So that serves as a benchmark for those patients. For the 1% to 49% group, the response rate generally sits at roughly 17% based on prior trials, particularly KEYNOTE-042. So the benchmark we're examining for pembrolizumab in that 1% to 49% patient group spans about a 15% to 20% response rate. Then lastly, for the subgroup at 50% or above PD-L1 expression, drawing on data from KEYNOTE-024 and also 42, the figures we're seeing land in the 40% to 50% range. That's the baseline response rate for pembrolizumab monotherapy. So to your point, given these subgroups, once we generate data on 30-plus patients, we'd examine it by breaking things out across each subgroup. That would let us fully grasp how our drug performs and also guide the design of our registrational study. So what we — the registrational trial for the pembro plus bempeg doublet, testing it against pembrolizumab monotherapy, will be confined to the 1%-and-above population, since pembro mono isn't approved below 1%. Still, the under 1% data coming out of PROPEL should be highly informative, because IL-2, being a known proinflammatory cytokine, ought to inflame the tumor. As demonstrated in our early phase data from PIVOT-02 on treatment biopsies — in our bladder cancer trial, for example — we showed that 7 out of 10 patients who had previously been PD-L1 negative, meaning PD-L1 expression under 1%, converted to PD-L1 positive following treatment, after just 1 cycle of bempeg. And so — I think this is where we genuinely hope to observe a similar phenomenon in non-small cell lung cancer within the PROPEL study. So even though pembro given alone is cleared for a wide range of patients, the groups I suspect will tell us the most are the under 1% cohort and the 1% to 48% — 1% to 49% cohort, since, first, those thresholds are low, and second, those thresholds are in fact quite low, so that if we show a periodic gain of, let's say, a doubling of the response rate, then we'd know the bempeg molecule has genuinely carried through its MOA the way we've observed in other tumor types — inflaming the tumor, particularly in tumors with low PD-L1 expression or none at all, to truly engage and inflame the tumor, making it sensitive to a checkpoint inhibitor like pembrolizumab. So we would certainly examine the data in a highly nuanced manner, pulling apart each subgroup and reading them on their own, hunting for truly robust signals that give us confidence we have a bempeg plus pembro combination able to meaningfully improve on the benefit pembrolizumab monotherapy provides to patients in first-line non-small cell lung cancer.
Jennifer Ruddock
executiveAnd JZ, do you want to take the CLASI-A versus SLEDAI question that...
Jonathan Zalevsky
executiveYes. George, thank you for bringing that up. So your question was about how CLASI and SLEDAI relate to one another. To begin, CLASI is a measure that hones in specifically on the skin-related signs of lupus, meaning it concentrates on the skin itself; it isn't tied in a direct way to the psoriasis SLEDAI, though we consistently pair CLASI with those other tools since we rely on them to describe lupus patients. That said, there's a key linkage to note, and keep in mind that lupus patients are defined by involvement of their secondary organs, and both SLEDAI and BILAG factor in those extra accessory tissues. Given that these scales contain multiple components, the scoring spans anything from whether autoantibodies are present or absent to whether secondary organs are involved or not, and then subcutaneous lupus will also add to the SLEDAI score. So some degree of connection exists; we've zeroed in on this because we're aware there's solid, long-established biology regarding Tregs and how they act, especially within the skin. As you know, at Lilly we've got 2 Phase Ib trials underway right now that center on dermal application, correct? In one of those, we're giving treatment to patients who have atopic dermatitis, and in the other trial, we're giving treatment to patients who have psoriasis. And if you recall from what David presented yesterday, he demonstrated that low-dose IL-2 produced a fair amount of efficacy among patients with psoriasis and other skin conditions, since he displayed that extensive table of patient phenotypes from those treated in the TRANSREG study; so truly, we're both tremendously excited and heartened that we observed a dose-dependent decrease in CLASI. The impact was genuinely striking. As you saw, a single patient who joined the study came in with fairly severe progressive skin involvement and a baseline score of 22. Over the treatment period, that patient experienced a reduction of 17 points on their CLASI. This patient was dosed at the highest level of NKTR-358. So that's a highly encouraging data point, and it aligns very, very well with the dose-dependent pattern we observe in Tregs, and it's among the primary reasons we're so thrilled to now be running the Phase IIb dose-range finding study alongside Lilly; that trial kicked off only a couple of months back during the summertime, and it's enrolling patients at present; and a second Phase II study is coming soon as well, in ulcerative colitis, with additional ones to follow next year.
Alexandre Bouilloux
analystThis is Alex sitting in for Difei. Sorry if somebody already covered this, but I have a quick question about non-small cell lung cancer and the bempeg combo with pembro. If the data coming out in the upcoming readouts turns out positive, what's the plan from here? And could there be a chance to go after something like an accelerated pathway to approval?
Jennifer Ruddock
executiveThanks, Alex. Wei, I'd like you to weigh in on that once more, briefly.
Wei Lin
executiveAbsolutely. Yeah, so, I mean, that sounds like a really good concept. It's definitely something we'd be open to pursuing with the regulatory agencies. Now, looking back, in the first-line treatment context, there hasn't been a precedent for accelerated approval grounded solely in response rate — certainly not, apart from something like a TKI such as <<inaudible>>. So at this point, that's something we'll need to investigate alongside the health authorities, and honestly, it hinges on how solid the data turns out to be from PROPEL.
Arlinda Lee
analystRegarding 358, because the Treg mechanism you presented yesterday could potentially apply quite broadly, I'm curious how you decided on those first 2 indications. And do you have any intention of looking into additional ones too?
Jennifer Ruddock
executiveThank you, Elanda. JZ, could you take that one?
Jonathan Zalevsky
executiveYes. Arlinda, that's a really good question. Regarding what Treg can be used for, there is certainly a very broad area of autoimmune conditions and chronic inflammatory diseases in which the Treg mechanism could be taken into consideration. It sort of splits into a few distinct pathobiologies; one major reason we chose SLE as our initial indication is that this disease shows a very clear, characteristic dysfunction within the Treg compartment. These patients, particularly as their disease becomes more severe over the course of progression, experience a decline in Treg numbers, and beyond that, the Tregs taken from those patients are much less suppressive, meaning they are far less functionally active; now, if you recall as well, David discussed T follicular helper cells yesterday. Those cells are antagonized by Tregs, and T follicular helper cells represent the primary T cells driving the germinal cellular reaction, which produces antibodies, and in autoimmune disease that is truly detrimental since it results in autoantibody production. And in those very patients who show a Treg decline, there is instead an expansion of T follicular helper cells. That was among the strongest reasons why certain early studies, in the earliest cases of treating lupus patients with low-dose IL-2 specifically to reduce a Treg increase in those patients, produced some of the highly encouraging results that have been reported. That finding has since been replicated across multiple studies. However, with low-dose IL-2, there is really only so much Treg normalization you can achieve. With NKTR-358, by contrast, we are able to reach far, far greater levels of Treg elevation and maintain those levels for much longer periods than low dose IL-2 makes possible. That is why this serves as a key lead indication for us. The second indication is ulcerative colitis. And this is actually quite interesting, because you see it is also another disease widely recognized as being characterized by Treg biology, and this biology involves a gut access, where a great deal of Treg function is tied to the lamina and other types of compartments in which pathologic T cell responses are being regulated in that disease. And unlike a disease such as lupus, which involves autoantibodies, a disease like UC has far fewer of them, but it does have underlying chronic inflammation with pathogenic T cells. And here, we know Tregs are capable of restoring those pathogenic T cell responses; it's also quite notable, Arlinda, that the earliest discovery of the FoxP3 cell, the cell originally termed T suppressor cell but later understood to be a Treg, in fact came out of studies in EAE, which is the mouse model of UC; so it's a very, very important related — and TNBS as well; so it's a very, very, very nice correlation that links to that; and then past these 2 lead indications, we are also evaluating, together with Eli Lilly, a number of additional indications. Through the partnership we formed alongside Lilly, that company is going to conduct 4 Phase II trials, and the initial one is already underway. Then just yesterday, news came out about the second one, which is receiving attention today in connection with UC. So 2 additional trials are in the process of getting started, and additional ones should appear over the course of next year. A range of indications will be sampled by us. That means they won't match the first 2; instead, our focus will land squarely on every area where, from a scientific standpoint, Treg biology combined with intervention using 358 ought to deliver a particularly potent disease-controlling impact.
Jay Olson
analystAlso, nice work on yesterday's 358 update. My question concerns what appears to be a rise in NK cells that depends on dose. How would you read those results?
Jennifer Ruddock
executiveJZ, that one's for you.
Jonathan Zalevsky
executiveYes. Jay, thanks for asking that. So we are seeing small elevations in NK cells. And really, we only saw this at the top dose we tested, which was 24 micrograms per kilogram. It's also worth pointing out that what we showed yesterday involved us digging into the NK subsets. There are a number of them, but the 2 main kinds found in humans are the CD56 bright, CD16 dim subset; those are unable to take part in ADCC. They can't bind to Fc since they don't have the CD16 receptor. Then you have the CD56 dim, CD16 bright. And the 16 dim — sorry, the 56 dim, 16 bright make up most of the NK cells in the body. They're also the most hyperactive ones, and they carry CD16, so they bind Fc and antibody receptors; and what you saw in our presentation is that we found very little shift in that compartment, while the bulk of the change showed up in the 56 bright, 16 dim. And in fact, many scientists view those as something like regulatory NK cells. The reason they get that label is that we don't secrete killer cytokines or inflammatory cytokines when stimulated. So they're nearly a type of cell whose function is the opposite of what you get with traditional NK cells; so that's one key piece; that's why we showed that data, Jay, to demonstrate the delineation and that this is truly a subset-specific effect. The other key point is that what we learned lines up very well with what's been understood and studied regarding IL-2 use across many historical applications; so we've consistently seen that the 56 bright, CD16 dim subset is far more sensitive to IL-2 than the other NK subset. And we've likewise seen the same NK cells elevated across multiple trials of low dose IL-2, and not only the trials from David Klatzmann lab, even in Kohn Koreth's trials in chronic graft-versus-host disease patients. We also observed an expansion of NK cells, only the 56 bright subset. And they truly haven't resulted in any sequela; so it's something we'll track in all of our trials because clearly, in Phase II, we'll be moving to a much longer treatment duration. And so we'll be examining that very, very carefully. But up to now, it doesn't appear that this has any clinically negative significance whatsoever.
Corinne Jenkins
analystCorinne Jenkins here, filling in for Paul. I was hoping you might be able to discuss your approach to melanoma a bit. My understanding is that you'll potentially have a combination in the adjuvant setting, plus 2 distinct combinations in metastatic melanoma. I was just hoping you could say a bit more about how you're thinking about all of those within that same indication.
Jennifer Ruddock
executiveYes. Thanks, Corinne. Wei, I'm going to ask you to weigh in on this. Thanks.
Wei Lin
executiveCertainly. Yeah. Could you perhaps expand on what you're referring to when you mention two separate combinations in the metastatic setting?
Corinne Jenkins
analystBempeg, next week. So I was just hoping, pending obviously positive data, but how would you think about development and kind of how those combinations worked together in that market?
Wei Lin
executiveMy apologies, I missed the beginning of your question.
Corinne Jenkins
analystGiven what we've seen in the SITC data for NKTR-262 and bempeg, along with the bempeg plus nivo trials you have running in metastatic melanoma, what's your thinking there?
Wei Lin
executiveRight, right, yes. So with 262, the population we're going after right now sits in the post-IO setting — meaning patients who have relapsed or are refractory to IO — whereas the bempeg plus nivo combo is genuinely being developed for first-line metastatic melanoma. So the way I see it, in that first-line setting we're attempting to do better than the current standard of care, which is nivolumab as a single agent, and build on it by bringing in a doublet combination of bempeg plus nivolumab, essentially pushing nivo out as the standard in that setting. Then, once a patient has failed IO therapy in the first-line setting — whether that was a checkpoint inhibitor or a PD-L1 plus a CTLA-4 combination — those are the patients, I think, who are really being addressed by the 2 combinations currently in our REVEAL study. That's the 262 program; the 2 combinations are the 262 molecule, a toll-like receptor 7/8, paired with bempeg, or the second one is a triplet of 262 plus bempeg plus nivolumab. So that's a triple combination. And each of those combinations is really meant to address a patient who has progressed on a checkpoint inhibitor in the first-line setting, whether through adding a toll-like receptor agonist, which would ignite innate immunity. Because so far, I think, whether you're discussing CTLA-4, or a PD-L1 agent, or a bempeg agent, which is IL-2 targeting T cells, all of them are essentially attempting to harness the body's adaptive immunity in the fight against cancer. The 262 agent, and any toll-like receptor agent, really goes the opposite direction, trying to trigger an immune response — trying to trigger adaptive immunity by activating innate immunity first. So — and I think some data with other toll-like receptor agents appears to suggest that's a viable strategy for really reigniting the immune response and really pulling in the adaptive immunity by first engaging and activating innate immunity through these intratumor injections of a toll-like receptor agonist. So — and I think what makes our strategy really unique is that, while the 262 or toll-like receptor strategy is being pursued by others too, we have the unique opportunity to add an IL-2 agent like bempeg to really provide an additional boost to that immunity. So really, you get an enhancement of the immune response tied to checkpoint inhibitors like nivolumab, and you get a double enhancement — on one hand with a toll-like receptor agonist such as 262 — so really trying to inflame the tumor and the immune response by activating innate immunity. Conversely, you're bringing in something such as bempeg, which genuinely boosts adaptive immunity. So when you put those together, I'd say this is among the distinctive pairings that really only Nektar is capable of doing, one that truly capitalizes on and works to trigger the immune response within an IO relapsed/refractory setting through turning on both adaptive and innate immunity. I'm hopeful that addresses what you asked.
Howard Robin
executiveAlright, thanks to each of you for being here; first off, I want to express appreciation to our amazing team members for the perseverance and relentless commitment they've shown through these difficult periods. The way they've stayed dedicated to pushing our clinical trials forward while also keeping our operations on course fills me with particular pride. As mentioned before, we're in a solid position, thanks to a robust balance sheet and a growing pipeline of immuno-oncology and immunology candidates, and we're grateful to our investors for their steady backing, and we anticipate bringing you further news about our advancements. Also, we'd love to have you with us at our analyst event on November 11. And finally, we truly wish that both you and your loved ones remain safe and well over the next several months. So, many thanks for being with us today.
Operator
operatorThat wraps up the call for today, everyone. We appreciate you joining us, and at this point you're free to leave the line. Wishing all of you a great rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.